Plain-English translation of NCT06632860 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new diagnostic imaging agent called that combines two targeting approaches to help detect certain cancers more effectively. The medication is designed to attach to cancer cells that have specific markers on their surface, making them easier to spot on a PET scan. Researchers believe this dual-targeting approach may find cancer that other standard scans miss, particularly when cancer has spread to the liver.
Current imaging scans sometimes miss certain cancers or don't show them as clearly as doctors would like. This treatment was developed to provide a more sensitive way to find these cancers early, which could lead to better treatment outcomes and potentially help guide future targeted therapies.
You likely qualify if…
You likely don't qualify if…
You would come to the hospital for two imaging scans that are scheduled within one week of each other. During each visit, you'll receive an injection of the new imaging medication, wait a short time for it to travel through your body, and then lie still in a PET/CT scanner for imaging. Each scan typically takes about 30 minutes to an hour total, and the study involves about 30 patients overall.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Safety & dosing
Sponsor
Peking Union Medical College Hospital
Enrollment target
~40 participants
Started
August 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 90 Years
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zhaohui Zhu
Peking Union Medical College Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.